Prostate Cancer | Specialty

The OncLive Prostate Cancer condition center page is a comprehensive resource for clinical news and expert insights on how to approach treatment for patients with nonmetastatic, castration-resistant, or castration-sensitive prostate cancer. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, ongoing research, and treatment advances with androgen receptor inhibitors, PARP inhibitors, and more in prostate cancer.

Dr. Sereti on the Preclinical Efficacy of NOV202 Plus Olaparib in BRCA1/2-Mutated Prostate Cancer

July 10th 2021

Evangelia Sereti, MSc, PhD, discusses the preclinical efficacy of NOV202 plus olaparib in BRCA1/2-mutated prostate cancer cells.

Dr. Wagaskar on the Rationale to Evaluate the Obesity Paradox in Prostate Cancer

July 10th 2021

Vinayak G. Wagaskar, MBBS, discusses the rationale to evaluate the relationship between obesity paradigm and outcomes in prostate cancer.

Dr. Tagawa on Tumor Targeting With Radionuclides in Prostate Cancer

July 8th 2021

Scott T. Tagawa, MD, MS, FACP, discusses tumor targeting with radionuclides in prostate cancer.

Adjuvant Radiation Therapy Could Yield Reduction in All-Cause Mortality in High-Risk Prostate Cancer

July 6th 2021

Men with positive pelvic lymph nodes or a prostatectomy Gleason score of 8 to 10 with disease extending beyond the prostate should be considered for treatment with adjuvant radiation therapy.

Rapid Readouts: Final Analysis of Phase 3 TITAN Trial

July 6th 2021

Scott T. Tagawa, MD, MS, FACP, reports on data presented at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting regarding health-related quality of life (HRQoL) and patient-reported outcomes (PROs) at the final analysis of TITAN, a phase 3 study evaluating apalutamide versus placebo in patients with metastatic castration-sensitive prostate cancer (mCSPC) who were receiving androgen deprivation therapy (ADT).

Mount Sinai Welcomes Robotic Prostate Surgery Pioneer Mani Menon, MD

June 30th 2021

Robotic prostate surgery pioneer Mani Menon, MD, is joining Mount Sinai and will serve as Chief of Strategy and Innovation in the Department of Urology for the Mount Sinai Health System.

Rapid Readouts: Extended Follow-up From the Phase 3 ARAMIS trial

June 30th 2021

Neal Shore, MD, presents data on the tolerability of and responses to darolutamide (DARO) as seen in the extended follow-up of the phase 3 ARAMIS trial of DARO treatment in men with high-risk, nonmetastatic, castration-resistant prostate cancer. The results were reported at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting.

Rapid Readouts: Treatment Preference Results From the Phase 2 ODENZA Trial

June 30th 2021

Neal Shore, MD, presents data on treatment preferences from the phase 2 ODENZA trial of darolutamide and enzalutamide in men with asymptomatic or mildly symptomatic metastatic castrate-resistant prostate cancer. The results were reported at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting.

VERU-111 Shows Potential for Safe, Long-Term Treatment in Metastatic CRPC

June 25th 2021

Eric Klein, MD, discusses the promise of VERU-111 in patients with metastatic CRPC and other research efforts that are generating excitement in the paradigm.

Dr. Shore on the Design of the ARAMIS Trial With Darolutamide in nmCRPC

June 24th 2021

Neal D. Shore, MD, FACS, discusses the design of the phase 3 ARAMIS trial in nonmetastatic castration-resistant prostate cancer.

Sequential 177Lu-PSMA-617 Plus Docetaxel Under Examination in Metastatic Hormone-Naïve Prostate Cancer

June 22nd 2021

Arun Azad, MBBS, PhD, FRACP, discusses the rationale that inspired the launch of the UpFrontPSMA trial, and highlights past and future research directions with 177Lu-PSMA-617 in the treatment of patients with prostate cancer.

Dr. Juárez Soto on the Efficacy of Apalutamide Plus ADT in mHSPC

June 21st 2021

Álvaro Juárez Soto, MD, discusses the efficacy of apalutamide plus androgen deprivation therapy in patients with metastatic hormone-sensitive prostate cancer.

Dr. Klein on the Rationale to Evaluate VERU-111 in mCRPC

June 21st 2021

Eric Klein, MD, discusses the rationale to evaluate VERU-111 in metastatic castration-resistant prostate cancer.

Bright White Light May Offset Negative Effects of ADT in Older Men With Prostate Cancer

June 20th 2021

Tanya Dorff, MD, discusses encouraging data from a study evaluating bright white light in older patients with prostate cancer and updates from the phase ARAMIS trial.

177Lu-PSMA-617 Receives FDA Breakthrough Therapy Designation for mCRPC

June 17th 2021

The FDA granted a breakthrough therapy designation to 177Lu-PSMA-617 for the treatment of patients with metastatic castration-resistant prostate cancer.

Dr. Juárez Soto on the Rationale for Apalutamide Plus ADT in mCSPC

June 17th 2021

Álvaro Juárez Soto, MD, discusses the rationale for examining apalutamide plus androgen deprivation therapy in patients with metastatic hormone-sensitive prostate cancer, as seen in the phase 3 TITAN study.

Dr. Choudhury on Emerging Treatment Strategies in mCRPC

June 15th 2021

Atish D. Choudhury, MD, PhD, discusses emerging treatment strategies in metastatic castration-resistant prostate cancer.

Dr. Pieczonka on the Design of the Phase 3 VERACITY Trial With VERU-111 in mCRPC

June 15th 2021

Christopher Pieczonka, MD, discusses the design of the phase 3 VERACITY trial studying VERU-111 in patients with metastatic castration-resistant prostate cancer.

Water Vapor Ablation Therapy Shows Encouraging Efficacy, Safety in Prostate Cancer

June 14th 2021

A water vapor ablation therapy has been shown to be able to reach and treat all prostate regions and eradicate intermediate risk, grade group 2 prostate cancer with acceptable safety and tolerability.

Addition of Abiraterone to ADT plus Docetaxel Yields Improvement in rPFS in De Novo mCSPC

June 9th 2021

Adding abiraterone acetate and prednisone to androgen-deprivation therapy plus docetaxel improved radiographic progression-free survival in patients with de novo metastatic castration-sensitive prostate cancer.